Meridian Bioscience Inc
VIVO
VIVO was delisted on the 30th of January, 2023.
216 hedge funds and large institutions have $1.35B invested in Meridian Bioscience Inc in 2022 Q2 according to their latest regulatory filings, with 33 funds opening new positions, 67 increasing their positions, 73 reducing their positions, and 22 closing their positions.
459% more call options, than puts
Call options by funds: $5.9M | Put options by funds: $1.05M
150% more funds holding in top 10
Funds holding in top 10: 2 → 5 (+3)
50% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 22
21% more capital invested
Capital invested by funds: $1.11B → $1.35B (+$232M)
3% more funds holding
Funds holding: 210 → 216 (+6)
8% less repeat investments, than reductions
Existing positions increased: 67 | Existing positions reduced: 73
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$36.2M |
| 2 |
FCM
Freshford Capital Management
Rye Brook,
New York
|
+$13.1M |
| 3 |
Renaissance Technologies
New York
|
+$5.33M |
| 4 |
N
Nuveen
Charlotte,
North Carolina
|
+$4.89M |
| 5 |
Neuberger Berman Group
New York
|
+$3.79M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EIP
Epoch Investment Partners
New York
|
-$14.5M |
| 2 |
RA
Royce & Associates
New York
|
-$9.2M |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$5.86M |
| 4 |
VLKIM
Van Lanschot Kempen Investment Management
Amsterdam,
Netherlands
|
-$5.71M |
| 5 |
BlackRock
New York
|
-$3.92M |
VIVO Hedge Fund Activity: Q2 2022 in Review
216 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Meridian Bioscience Inc (VIVO) for Q2 2022, worth a combined $1.35B — up 21% from $1.11B a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new VIVO positions and 22 closed out — a net gain of 11 holders — while 67 added to existing stakes and 73 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $36.2M. The largest seller was Epoch Investment Partners, cutting an estimated $14.5M.
- 216 institutional investors held Meridian Bioscience Inc (VIVO) as of Q2 2022, up from 210 in Q1 2022.
- Funds reported $1.35B of Meridian Bioscience Inc stock for Q2 2022, up 21% quarter-over-quarter.
- 33 funds opened new Meridian Bioscience Inc positions in Q2 2022 and 22 closed out, a net change of +11 holders.
- The largest Meridian Bioscience Inc buyer in Q2 2022 was Fidelity Investments, an estimated $36.2M added.
- The largest Meridian Bioscience Inc seller in Q2 2022 was Epoch Investment Partners, an estimated $14.5M sold.
Based on aggregated 13F filings for Q2 2022.